Results from a just-published landmark trial could lead to the first-ever approved drug for the treatment of systemic scleroderma-associated interstitial lung disease.
Read MoreImproving Treatment Outcomes for Patients with Rheumatic Lung Disease
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
1-Minute Consult: What Is the Role of Roflumilast in COPD?
Roflumilast’s benefit-to-harm ratio suggests that it only provides net benefit in patients at high risk of severe exacerbations.
Surfactant Replacement Therapy in ARDS
Revising approaches to surfactant replacement therapy may improve on results of prior clinical trials to combat acute respiratory distress syndrome.
Transplant Drug Wins FDA Approval for Rare Lung Disease
Rapamycin — an FDA-approved drug to prevent organ rejection in kidney transplant patients — is providing hope for patients affected by a rare lung disease that almost exclusively affects women.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy